IL-28B genotypes as predictors of long-term outcome in patients with hepatitis C-related severe liver injury

Authors

  • Jelena Jordovic Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
  • Jasmina Simonovic-Babic Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
  • Vladimir Gasic Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
  • Nikola Kotur Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade
  • Branka Zukic Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade
  • Sonja Pavlovic Medical Faculty, University of Belgrade, Belgrade, Serbia
  • Ivana Lazarevic Institute of Microbiology and Immunology, Belgrade, Serbia
  • Danijela Karalic Institute of Microbiology and Immunology, Belgrade, Serbia
  • Natasa Katanic Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
  • Natasa Nikolic Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
  • Aleksandar Urosevic Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
  • Jelena Nestorov Medical Faculty, University of Belgrade, Belgrade, Serbia
  • Dragan Delic Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia
  • Ksenija Bojovic Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia

DOI:

https://doi.org/10.3855/jidc.11351

Keywords:

interleukine 28B, late relapse, outcome

Abstract

Introduction: Patients with severe fibrosis or cirrhosis are at high risk for liver-related complications, even after successful antiviral treatment and/or regression of fibrosis. These are the first published results concerning the role of IL-28B genotypes as predictors of the durability of sustained virological response (SVR) and long-term outcome, in patients with baseline severe fibrosis and cirrhosis caused by hepatitis C (HCV) infection.

Methodology: Genetic testing for three different single nucleotide polymorphisms (SNP) near the IL28B gene, rs12979860, rs12980275 and rs8099917, was performed in 42 patients with HCV-related advanced fibrosis and cirrhosis, who achieved SVR after successful interferon-based treatment. Baseline clinical and laboratory parameters were analysed, as well as IL28B genotype association with late virological relapse, fibrosis progression and clinical outcomes.

Results: The most prevalent genotypes in all three tested SNP positions were: CCrs12979860 genotype in 69% of patients, GTrs8099917 in 78.6% and GGrs12980275 in 47.6% of patients. The presence of IL28B CCrs12979860 genotype was identified as a negative predictor of late virological relapse. Further analysis did not confirm the association of other IL28B genotypes with the progression of fibrosis and clinical outcomes.

Conclusions: Varying long-term prognosis in patients with HCV-related severe fibrosis and cirrhosis is due to multiple interactions between host genetic factors, virus and environment. These are first published results demonstrating the significance of IL28B CCrs12979860 genotype as a negative predictor of late virological relapse. A further investigation concerning genetic factors is necessary to identify patients under risk for late relapse, complications and unfavorable outcomes, so that they can be reevaluated and offered new treatment options.

Downloads

Published

2019-05-31

How to Cite

1.
Jordovic J, Simonovic-Babic J, Gasic V, Kotur N, Zukic B, Pavlovic S, Lazarevic I, Karalic D, Katanic N, Nikolic N, Urosevic A, Nestorov J, Delic D, Bojovic K (2019) IL-28B genotypes as predictors of long-term outcome in patients with hepatitis C-related severe liver injury. J Infect Dev Ctries 13:526–535. doi: 10.3855/jidc.11351

Issue

Vol. 13 No. 06: June 2019

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC